More than 100-year-old flu virus sequenced
Swiss Genome of the 1918 Influenza Virus Reconstructed
Advertisement
Researchers from the universities of Basel and Zurich have used a historical specimen from UZH’s Medical Collection to decode the genome of the virus responsible for the 1918–1920 influenza pandemic in Switzerland. The genetic material of the virus reveals that it had already developed key adaptations to humans at the outset of what became the deadliest influenza pandemic in history.
New viral epidemics pose a major challenge to public health and society. Understanding how viruses evolve and learning from past pandemics are crucial for developing targeted countermeasures. The so-called Spanish flu of 1918–1920 was one of the most devastating pandemics in history, claiming some 20 to 100 million lives worldwide. And yet, until now, little has been known about how that influenza virus mutated and adapted over the course of the pandemic.
More than 100-year-old flu virus sequenced
An international research team led by Verena Schünemann, a paleogeneticist and professor of archaeological science at the University of Basel (formerly at the University of Zurich) has now reconstructed the first Swiss genome of the influenza virus responsible for the pandemic of 1918–1920. For their study, the researchers used a more than 100-year-old virus taken from a formalin-fixed wet specimen sample in the Medical Collection of the Institute of Evolutionary Medicine at UZH. The virus came from an 18-year-old patient from Zurich who had died during the first wave of the pandemic in Switzerland and underwent autopsy in July 1918.
Three key adaptations in Swiss virus genome
“This is the first time we’ve had access to an influenza genome from the 1918–1920 pandemic in Switzerland. It opens up new insights into the dynamics of how the virus adapted in Europe at the start of the pandemic,” says last author Verena Schünemann. By comparing the Swiss genome with the few influenza virus genomes previously published from Germany and North America, the researchers were able to show that the Swiss strain already carried three key adaptations to humans that would persist in the virus population until the end of the pandemic.
Two of these mutations made the virus more resistant to an antiviral component in the human immune system – an important barrier against the transmissions of avian-like flu viruses from animals to humans. The third mutation concerned a protein in the virus’s membrane that improved its ability to bind to receptors in human cells, making the virus more resilient and more infectious.
New genome-sequencing method
Unlike adenoviruses, which cause common colds and are made up of stable DNA, influenza viruses carry their genetic information in the form of RNA, which degrades much faster. “Ancient RNA is only preserved over long periods under very specific conditions. That’s why we developed a new method to improve our ability to recover ancient RNA fragments from such specimens,” says Christian Urban, the study’s first author from UZH. This new method can now be used to reconstruct further genomes of ancient RNA viruses and enables researchers to verify the authenticity of the recovered RNA fragments.
Invaluable archives
For their study, the researchers worked hand in hand with UZH’s Medical Collection and the Berlin Museum of Medical History of the Charité University Hospital. “Medical collections are an invaluable archive for reconstructing ancient RNA virus genomes. However, the potential of these specimens remains underused,” says Frank Rühli, co-author of the study and head of the Institute of Evolutionary Medicine at UZH.
The researchers believe the results of their study will prove particularly important when it comes to tackling future pandemics. “A better understanding of the dynamics of how viruses adapt to humans during a pandemic over a long period of time enables us to develop models for future pandemics,” Verena Schünemann says. “Thanks to our interdisciplinary approach that combines historico-epidemiological and genetic transmission patterns, we can establish an evidence-based foundation for calculations,” adds Kaspar Staub, co-author from UZH. This will require further reconstructions of virus genomes as well as in-depth analyses that include longer intervals.
Original publication
Christian Urban, Bram Vrancken, Livia V. Patrono, Ariane Düx, Mathilde Le Vu, Katarina L. Matthes, Nina Maria Burkhard-Koren, Navena Widulin, Thomas Schnalke, Sabina Carraro, Frank Rühli, Philippe Lemey, Kaspar Staub, Sébastien Calvignac-Spencer, Verena J. Schuenemann; "An ancient influenza genome from Switzerland allows deeper insights into host adaptation during the 1918 flu pandemic in Europe"; BMC Biology, Volume 23, 2025-7-1
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Attracting bright and bold minds: new ideas for genome diagnostics and single molecule sensing - Four innovative life sciences ideas with particular economic potential receive awards
Deepest look yet into the human genome - A new resource for genome research worldwide
Researchers identify a potential biomarker for long COVID - Extracellular vesicles in study participants contain SARS-CoV-2 peptides
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration - Joint research program targets new treatments for life-threatening complication of brain hemorrhage
Merck (MSD) to acquire Verona Pharma for $10 billion - The acquisition strengthens the company's position in the field of COPD treatments
Takeda strengthens Berlin site as future German headquarters - The Constance site will be closed by the end of 2028
QIAGEN acquires bioinformatics company - Expanding clinical bioinformatics capabilities in molecular oncology
Remdesivir disrupts COVID-19 virus better than other similar drugs - How the COVID-19 drug remdesivir works at the molecular level
Scientists identify 160 new drugs that could be repurposed against COVID-19 - Forty of these drugs have already entered clinical trials
Transparency for clinical trials - Transparency of study results in a public dashboard
Bertelsmann Investments acquires stake in AI-powered Israeli healthcare startup QuantHealth - AI-supported start-up company for clinical trial planning
